Sanofi Builds Blood Disorder Specialty With Bioverativ Buy
The French drug maker is making a big splash into blood disorders with the $11.6bn acquisition of hemophilia specialist Bioverativ. Eloctate and Alprolix are young and growing brands, but the competition in hemophilia is fierce, which means Bioverativ's pipeline will also need to deliver to justify the premium price.
You may also be interested in...
Flagship Pioneering combined Torque Therapeutics and Cogen Immune Medicines, which have raised more than $220m, into Repertoire Immune Medicines with an autologous T-cell therapy being studied in a Phase I trial.
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
In CEO Paul Hudson's first earnings call at the company's helm, he said he has big goals for driving growth but a deeper strategic update will be outlined to investors on Dec. 10 in Cambridge, Mass.